Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 16;107(6):734–745. doi: 10.1111/cas.12933

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Fucosidase, α‐l‐1 (FUCA1) function is lost/decreased in human cancers and low FUCA1 expression is related to poorer prognosis of cancer patients. (a) FUCA1 mutations found in human cancers are shown. Data were obtained from the COSMIC database. (b,c) FUCA1 (NM_000147) expression in colorectal and rectal cancer was analyzed using the ONCOMINE database. Left and right boxes show the results obtained with normal and cancer tissues, respectively. (b) FUCA1 (probe A_23_P11543) expression in Gaedcke colorectal adenocarcinoma versus normal colorectal tissue was analyzed. FUCA1 was positioned 896th in a ranking of underexpressed genes (in top 5%). P‐value, 7.29E−22; fold‐change, –2.676. (c) FUCA1 (probe 202838_at) expression in Skrzypczak colorectal carcinoma versus normal rectal tissue was analyzed. FUCA1 was positioned 6th in a ranking of underexpressed genes (in top 1%). P‐value, 4.98E−20; fold‐change, –2.976. (d–f) FUCA1 prognostic analysis was carried out using the PrognoScan database. (d) Using the PrognoScan database, FUCA1 expression was analyzed using two probes, 202838_at and 229137_at. In total, 101 datasets were available for FUCA1 expression. Pie charts are shown for each end point. The datasets were categorized into seven categories according to Cox P‐values and hazard ratios (HR) (d, right). Lower FUCA1 expression showed significant associations with poorer prognosis in patients with cancers of the large intestine, breast, or lung. (e,f) Datasets for colorectal (e) and breast (f) cancers are shown. (g–j) Representative survival curves showing the prognosis of colorectal (g,h) and breast (i,j) cancer patients with high or low FUCA1 expression. (g,h) Overall survival of colorectal cancer patients of datasets GSE17536 (n = 177; HR (95% confidence interval [CI]) = 0.15 [0.03–0.68], P = 0.01) and GSE17537 (n = 55; HR [95% CI] = 0.04 [0.00–0.61], P = 0.02). (i) Overall survival of breast cancer patients of dataset GSE1456GPL96 (n = 159; HR [95% CI] = 0.42 [0.20–0.89], P = 0.02). (j) Distant metastasis‐free survival of breast cancer patients of dataset GSE11121 (n = 200; HR [95% CI] = 0.29 [0.14–0.60], P = 0.0007).